Revinax SAS

Revinax SAS is a healthcare technology company that specializes in innovative training solutions utilizing immersive virtual reality (VR) technology to enhance medical professional training and safety practices. Founded in 2015 and headquartered in Montpellier, France, Revinax SAS focuses on developing advanced training solutions for the healthcare sector. The company has executed a total of 4 deals, with its most recent funding round, a Series A, occurring on October 28, 2019. Revinax successfully raised EUR 0.

007 mn in this round, bringing its total amount raised to EUR 0. 007 mn and valuing the company at EUR 6. 231 mn post-money. The company is led by CEO and founder Maxime Ros, who has a history in leading healthcare technology initiatives.

Revinax SAS offers immersive training solutions for the healthcare industry, primarily through virtual reality technology. Their main product consists of first-person perspective stereoscopic (3D) tutorials that allow learners to engage with medical procedures as if they were the executing professionals. This experiential learning approach enhances practitioner confidence and retention rates. The solutions cater to a variety of end users, including medical professionals and institutions, and are compatible with multiple platforms such as VR headsets, smartphones, tablets, and computers, making them accessible to a broad audience in both European and North American markets.

Revinax SAS operates on a business-to-business (B2B) model, generating revenue through licensing immersive training programs and tailored content for healthcare institutions and practitioners. Their transactions typically involve subscription-based agreements, providing clients access to a comprehensive library of VR training modules and ongoing support services. The company also offers an immersive experience that integrates with existing training protocols, enhancing client value. While specific revenue figures are proprietary, their focus on innovation in medical training supports a robust revenue generation strategy.

Revinax SAS aims to further develop its product offerings, including new immersive training modules tailored for specific medical procedures. The company plans to expand into new international markets, particularly targeting regions in Asia by 2024. The recent Series A funding of EUR 0. 007 mn will be utilized to support these product developments and market expansion initiatives, positioning Revinax for sustainable growth in the healthcare training sector.